Enforcement Report - Week of March 29, 2023
Enforcement Report - Week of December 7, 2022
Enforcement Report - Week of July 6, 2022
Enforcement Report - Week Of June 01, 2022
Mylan Tech Viatris' Generic Methylphenidate Receives Approval in the U.S.
Enforcement Report - Week of March 10, 2021
Actavis Elizabeth’s Generic Methylphenidate Receives Approval In US
Adlon Therapeutics L.P. and Purdue Pharma L.P. will present data from three studies evaluating PRC-063 at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting in Washington D.C. PRC-063 was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older and is currently available as Adhansia XRâ„¢ (methylphenidate hydrochloride) extended-release capsules CII.
The US Food and Drug Administration (FDA) on Thursday opened a public consultation to gather input on the development and evaluation of abuse-deterrent formulations (ADF) of central nervous system (CNS) stimulants.
The world's master list of recommended medicines got an update on Tuesday when the World Health Organization (WHO) published a biennial revision, adding 28 drugs including an abortion pill but leaving out several breakthrough treatments for lung cancer.